Ketoconazole high dose (H.D.) in the management of hormonally pretreated patients with progressive metastatic prostate cancer.
Ketoconazole high dose (H.D.) reduces effectively the testosterone production in both adrenals and testes. Its use in the management of (metastatic) prostate cancer has been advocated. Even in relapsing patients after previous hormonal therapy Ketoconazole H.D. could be of value. 28 Relapsing patients, of whom 15 were evaluable at 3 months, have been treated with Ketoconazole H.D. As could be expected, objective response was seen in only a small number of patients followed up till 9 months. Subjective improvement was however noticed in the majority of symptomatic patients. The side effects and toxicity of the therapy remains however a major limitation for the use of Ketoconazole, be it as first line treatment or as therapy for relapsing patients.
Debruyne
F M
FM
Department of Urology, St. Radboudhospital, Cath. University, Nijmegen, The Netherlands.
Witjes
F A
FA
D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007654:Ketoconazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D008297:Male; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
D004967:Estrogens; D013739:Testosterone; D007654:Ketoconazole; D006854:Hydrocortisone